BUZZ-Genmab rises on upbeat 2025 sales forecast

U.S.-listed shares of Denmark-based drugmaker Genmab GMAB.CO, GMAB.O up 1.9% to $19.24

Company, which develops cancer treatments, sees 2025 sales to be in the range of $3.3 billion to $3.7 billion, banking on strong demand for its blood cancer treatment Darzalex

Analysts were expecting revenue of $3.56 billion on average for 2025 — LSEG

Genmab partnered with Johnson & Johnson JNJ.N for Darzalex

Partner JNJ reported full-year sales of Darzalex rose 20.6% to $11.67 billion in 2024

Expects 2025 operating expenses to be in the range of $2.1 billion to $2.2 billion due to ongoing late-stage studies of cancer treatments and potential planned launches

In the last 12 months, stock has fallen 31.1%